Cell and Gene Outsourcing

  1. What Makes A Base Editor Potent For Therapeutic SNP Correction? 9/7/2026

    Therapeutic SNP correction requires tailored enzymes and guide RNAs to boost on-target editing, reduce bystander effects, and enable precise conversion.

  2. The Next Base Editors Will Be Engineered, Not Found 9/7/2026

    Transitioning from wild-type enzymes to AI-engineered base editors overcomes biological limits. Custom deaminases enable precise single-nucleotide corrections with minimal bystander edits.

  3. Rapid Release Testing Starts With Faster Contaminant Detection 9/7/2026

    Switch to rapid sequencing-based contaminant detection to accelerate advanced therapy release timelines, minimize batch rejection risks, and bypass slow, culture-based testing methods.

  4. Can LNPs Replace Electroporation For T-Cell Engineering? 9/7/2026

    Replacing electroporation with lipid nanoparticles enables efficient non-viral T cell delivery, preserving cell health while supporting scalable manufacturing and high delivery performance.

  5. How Can AI-Directed Protein Engineering Improve Genomic Medicines? 9/7/2026

    Combining AI-driven modeling with automated cell profiling speeds protein optimization, identifying high-performing enzyme variants with greater potency and precision for genomic medicine applications.

  6. Targeted Gene Insertion Needs More Than One Tool 9/7/2026

    Targeted large gene insertion depends on matching the right mechanism to the biology. Engineered enzymes, recombinases, and retrotransposons help optimize efficiency and precision.

  7. Accelerating CAR T-Cell Therapy Manufacturing For Autoimmune Disease 9/7/2026

    Proactive alignment and integrated quality systems can shorten cell therapy timelines. Rapid tech transfer and in-house analytics support regulatory rigor and reduce scaling risks.

  8. When Should You Engage A Cell And Gene Therapy CDMO? Earlier Than You Think 9/7/2026

    Involving manufacturing partners early helps prevent costly bottlenecks. Production expertise strengthens process design, reduces tech transfer risk, and keeps advanced therapy programs on track.

  9. Technology, Not Just Biology, Will Deliver The Future Of Medicine 9/7/2026

    Scaling advanced therapies requires engineering-driven biomanufacturing. Modular automation, standardized platforms, and real-time analytics reduce bottlenecks, speed approvals, and improve access.

  10. Rapid Sterility And Adventitious Agent Testing 9/7/2026

    44-to-72-hour NGS release testing replaces lengthy culture assays, rapidly detecting viral, fungal, and bacterial contaminants to accelerate product release while maintaining patient safety.